NewsPronto

 
Men's Weekly

.

ACN Newswire

Read more press releases from ACN Newswire here

Results from Clinical Trials of Penpulimab in Combination with Anlotinib for 1L HCC Co-developed by Sino Biopharmaceutical and Akeso Accepted for Presentation at ASCO Annual Meeting

  • Written by ACN Newswire

image

HONG KONG, May 19, 2020 - (ACN Newswire) - Sino Biopharmaceutical Limited (HKEX: 1177), a leading, innovative research and development ("R&D") driven pharmaceutical conglomerate in the PRC, has announced that the abstracts on phase II study on clinical efficacy and safety of Penpulimab (AK105, PD-1 monoclonal antibody) it jointly developed...

Read more: Results from Clinical Trials of Penpulimab in Combination with Anlotinib for 1L HCC Co-developed...